Bioventures Investors logo

Bioventures Investors

North America, Massachusetts, United States, Wellesley

Description

Bioventures Investors is a specialized venture capital firm based in Wellesley, Massachusetts, dedicated to fostering the commercial development of advanced technology within the life sciences and healthcare sectors. The firm distinguishes itself by focusing on innovative companies poised for significant impact, particularly those with robust intellectual property and seasoned management teams. Their investment philosophy centers on identifying and nurturing enterprises that offer clear pathways to market commercialization, aligning with their mission to advance critical medical and biotechnological innovations.

The firm typically engages with companies in their early to growth stages, often participating in Series A or Series B funding rounds. Bioventures Investors is known for its substantial financial backing, having successfully raised and deployed multiple funds. For instance, their BioVentures V fund closed at $200 million, followed by BioVentures VI, which secured $250 million. These significant capital pools enable the firm to make meaningful initial investments, ranging from $5 million to $15 million, with the flexibility to provide additional capital as portfolio companies mature and scale.

Beyond capital infusion, Bioventures Investors adopts a hands-on approach, leveraging their deep industry expertise and extensive network to support their portfolio companies. They aim to be strategic partners, assisting with operational guidance, business development, and navigating complex regulatory landscapes inherent in the life sciences. This comprehensive support system is designed to accelerate the development and market entry of groundbreaking healthcare solutions, reinforcing their commitment to driving innovation from concept to commercial success.

Investor Profile

Bioventures Investors has backed more than 36 startups, with 0 new investments in the last 12 months alone. The firm has led 7 rounds, about 19% of its total and boasts 9 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Series Unknown, Series B rounds (top funding stages).
  • Majority of deals are located in United States, Israel.
  • Strong thematic focus on Health Care, Biotechnology, Medical.
  • Typical check size: $5M – $15M.

Stage Focus

  • Series A (25%)
  • Series Unknown (25%)
  • Series B (22%)
  • Series C (14%)
  • Series D (11%)
  • Series E (3%)

Country Focus

  • United States (97%)
  • Israel (3%)

Industry Focus

  • Health Care
  • Biotechnology
  • Medical
  • Medical Device
  • Pharmaceutical
  • Genetics
  • Health Diagnostics
  • Software
  • Life Science
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Bioventures Investors frequently co-invest with?

Abingworth
Europe, England, United Kingdom, London
Co-Investments: 3
SV Health Investors
North America, Massachusetts, United States, Boston
Co-Investments: 3
Accelerated Technologies Partners
North America, New York, United States, New York
Co-Investments: 2
Mitsui Global Investment
North America, California, United States, Menlo Park
Co-Investments: 3
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 2
Commons Capital
North America, Massachusetts, United States, Brookline
Co-Investments: 2
Polaris Partners
North America, Massachusetts, United States, Boston
Co-Investments: 3
Oxford Bioscience Partners
North America, Massachusetts, United States, Boston
Co-Investments: 4
Advanced Technology Ventures
North America, California, United States, Menlo Park
Co-Investments: 4
Lilly Ventures
North America, Indiana, United States, Indianapolis
Co-Investments: 5

Which angels does Bioventures Investors often collaborate with?

KL
North America, Ohio, United States, Cleveland
Shared Deals: 1

What are some of recent deals done by Bioventures Investors?

Georgiamune

Gaithersburg, Maryland, United States

Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.

BiotechnologyHealth CareTherapeutics
Series AAug 9, 2023
Amount Raised: $75,000,000
BRAINBox Solutions

Richmond, Virginia, United States

BRAINBox provides objective evidence of injury and prediction of patient recovery.

BiotechnologyHealth CareWellness
Series ADec 8, 2020
Amount Raised: $23,000,000
Sonomotion

South San Francisco, California, United States

Sonomotion is a medical device manufacturing company that specializes in providing medical solutions for kidney stones disease.

Clinical TrialsInnovation ManagementManufacturingMedical Device
Series BNov 12, 2019
Amount Raised: $10,000,000
Endotronix

Lisle, Illinois, United States

Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before.

BiotechnologyHealth CareMedicalMedical DeviceSoftwareWireless
Series DSep 14, 2018
Amount Raised: $70,000,000
Unified Information Devices

Lake Villa, Illinois, United States

Unified Information Devices is a Identification Solutions.

BioinformaticsConsumer ResearchHealth CareiOSSoftware
Series UnknownJul 10, 2018
Amount Raised: $2,460,000
CoNextions Medical

Salt Lake City, Utah, United States

CoNextions Medical manufactures tendon repair surgical healthcare equipment.

Health CareMedical DeviceWellness
Series UnknownMar 16, 2017
Amount Raised: $2,163,000
POC Medical Systems

Livermore, California, United States

POC (Point-Of-Care) Medical Systems. Next generation diagnostics for a better life.

Health DiagnosticsMedicalMedical Device
Series AJan 10, 2017
Amount Raised: $21,000,000
Endotronix

Lisle, Illinois, United States

Endotronix is a developer of hemodynamic monitoring technologies to help detect worsening heart failure earlier than ever before.

BiotechnologyHealth CareMedicalMedical DeviceSoftwareWireless
Series CJul 5, 2016
Amount Raised: $37,100,866
InSeal Medical

Caesarea, Hefa, Israel

The InSeal technology is based on an internal biodegradable membrane which seals the puncture.

Information Technology
Series UnknownJan 2, 2012
Cylene Pharmaceuticals

San Diego, California, United States

Cylene Pharmaceuticals discovers, develops and commercializes small molecule drugs that target nucleolus and kill cancer cells.

BiotechnologyHealth CarePharmaceutical
Series DSep 24, 2010
Amount Raised: $12,000,000